Project 2 - Abstract. We view cancer as an open complex adaptive system that can be characterized using necessary and sufficient data, eco-evolutionary first principles and sophisticated computational methods. Here we examine perturbations of that system through therapy. We propose that optimization of treatment requires solid understanding of the underlying dynamics which, in turn, permits accurate predictions of its response to any therapeutic perturbation. . We will focus our efforts on three of these teams each of which will concentrate on active clinical trials that investigate different tumors (multiple myeloma, prostate cancer and glioblastoma) treated with different therapeutic strategies (multidrug chemotherapy, hormonal treatment, and immunotherapy). In each trial, the multidisciplinary team will apply an existing computational model that captures the intratumoral evolutionary and ecological dynamics using available clinical data. The general goal is to predict response and resistance to therapy in each patient. Using an iterative approach, each team will work with the B2B core and Project 1 to optimize the models' predictive power by exploring alternative mathematical methods and inclusion of new data elements from each trial (e.g. multi-parametric imaging, circulating tumor cells, etc.). In follow-on trials using the same tumors and treatment strategies, we will validate model predictions, apply variations in the treatment approaches (or combinations of approaches) suggested by parallel pre-clinical experiments in Project 1 and model simulations in the B2B core.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA193489-05
Application #
9774761
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2019-09-01
Budget End
2020-08-31
Support Year
5
Fiscal Year
2019
Total Cost
Indirect Cost
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
Subramanian, Hemachander; Gatenby, Robert A (2018) Evolutionary advantage of directional symmetry breaking in self-replicating polymers. J Theor Biol 446:128-136
Shah, Seema; Brock, Ethan J; Jackson, Ryan M et al. (2018) Downregulation of Rap1Gap: A Switch from DCIS to Invasive Breast Carcinoma via ERK/MAPK Activation. Neoplasia 20:951-963
Karolak, Aleksandra; Rejniak, Katarzyna A (2018) Micropharmacology: An In Silico Approach for Assessing Drug Efficacy Within a Tumor Tissue. Bull Math Biol :
Shah, Seema; Brock, Ethan J; Ji, Kyungmin et al. (2018) Ras and Rap1: A tale of two GTPases. Semin Cancer Biol :
Gallaher, Jill A; Enriquez-Navas, Pedro M; Luddy, Kimberly A et al. (2018) Spatial Heterogeneity and Evolutionary Dynamics Modulate Time to Recurrence in Continuous and Adaptive Cancer Therapies. Cancer Res 78:2127-2139
Maley, Carlo C; Aktipis, Athena; Graham, Trevor A et al. (2017) Classifying the evolutionary and ecological features of neoplasms. Nat Rev Cancer 17:605-619
Ibrahim-Hashim, Arig; Robertson-Tessi, Mark; Enriquez-Navas, Pedro M et al. (2017) Defining Cancer Subpopulations by Adaptive Strategies Rather Than Molecular Properties Provides Novel Insights into Intratumoral Evolution. Cancer Res 77:2242-2254
Brown, Joel S; Cunningham, Jessica J; Gatenby, Robert A (2017) Aggregation Effects and Population-Based Dynamics as a Source of Therapy Resistance in Cancer. IEEE Trans Biomed Eng 64:512-518
Gatenby, Robert A; Brown, Joel (2017) Mutations, evolution and the central role of a self-defined fitness function in the initiation and progression of cancer. Biochim Biophys Acta Rev Cancer 1867:162-166
Silva, Ariosto; Silva, Maria C; Sudalagunta, Praneeth et al. (2017) An Ex Vivo Platform for the Prediction of Clinical Response in Multiple Myeloma. Cancer Res 77:3336-3351

Showing the most recent 10 out of 22 publications